Genome engineering to introduce a fluorescent reporter into human pluripotent stem cells to study cardiac disease
In this free webinar, Lise Munsie, Development Scientist at CCRM, discusses the need for and creation of a standard protocol for efficient genome engineering in human PSCs enabled with Gibco StemFlex Medium.
The use of pluripotent stem cell-derived cell types for disease modeling, drug screening and regenerative medicine is an exciting area of activity in health research. Prior to the availability of pluripotent stem cells and differentiation methods, relevant and affected primary cells were difficult to obtain and frequently only accessible post-mortem. Additionally, the recent development of CRISPR/Cas9 based genome editing methods allow the creation of isogenic (matched) disease and control lines that differ only at a specific, disease-relevant locus, or to insert reporter constructs into PSC lines such that the reporter may be used to study disease biology in relevant cell types after differentiation. Recently, CCRM has created a standard protocol for efficient genome engineering in human pluripotent stem cells (hPSC).
This talk will describe our protocol, and its application to the creation of a cell line that contains a voltage-sensitive fluorescent reporter that will be used to study cardiac function and disease.
What will you learn?
- Overview of protocol CCRM has developed for genome editing
- Application of protocol to the creation of a cell line that contains a voltage-sensitive fluorescent reporter that will be used to study cardiac function and disease
- How StemFlex™ Medium was used to enable the protocol
Who may this interest?
- Stem cell researchers
Dr. Lise Munsie currently holds the position of Development Scientist at CCRM. She obtained her PhD in the department of Biochemistry and Biomedical Science at McMaster University and held a 3-year postdoctoral fellowship at the University of British Columbia (UBC), jointly between the department of Medical Genetics and the department of Neuroscience. At CCRM, a leader in developing and commercializing regenerative medicine technologies, and cell and gene therapies, Lise oversees a variety of projects related to iPSC derivation, directed differentiation and genome engineering.
For a full list of other webinars available on RegMedNet please see here.